Bank of America Merrill Lynch Reiterates Buy Rating, $25 PT on Pfizer

Loading...
Loading...
In a report published Monday, Bank of America Merrill Lynch reiterated its Buy rating and $25.00 price target on Pfizer
PFE
. BofA Merrill Lynch noted, “Given the upcoming FDA PDUFA data for PFE's novel treatment for RA (tofacitinib), the recent Complete Response letter for Eliquis and the upcoming data for bapineuzumab, we expect all three of these drugs to be points of focus on the call. We will also be paying attention to updated financial details (proceeds to PFE) on the sale of the nutrition business as well as any commentary on the sale/spin of the Animal Health business.” Pfizer closed on Friday at $23.70.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsBank of America Merrill Lynch
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...